

Target Cell Range of *Haemophilus ducreyi* Hemolysin and Its Involvement in Invasion of Human Epithelial Cells

GWENDOLYN E. WOOD, SUSAN M. DUTRO, AND PATRICIA A. TOTTEN*

Department of Medicine, Division of Infectious Diseases, University of Washington, Seattle, Washington

Received 19 January 1999/Returned for modification 2 April 1999/Accepted 10 May 1999

***Haemophilus ducreyi*, the causative agent of chancroid, produces a hemolysin, whose role in virulence is not well defined. To assess the possible role of hemolysin in pathogenesis, we evaluated its target cell range by using wild-type *H. ducreyi* 35000, nonhemolytic mutants with the hemolysin structural gene deleted, and isogenic strains expressing different amounts of hemolytic activity. The cytotoxicity of the various cell types was assessed by quantitating the release of lactate dehydrogenase into culture supernatants as a measure of cell lysis. In these experiments, human foreskin fibroblasts, human foreskin epithelial cells, and, to a lesser extent, HEp-2 cells were lysed by *H. ducreyi* hemolysin. Hemolysin also lysed human blood mononuclear cells and immune system cell lines including U937 macrophage-like cells, T lymphocytes, and B lymphocytes. In contrast, human polymorphonuclear leukocytes were not sensitive to hemolysin under the conditions tested. We also analyzed the effect of hemolysin on invasion of human epithelial cells and found that *H. ducreyi* strains expressing cloned hemolysin genes showed a 10-fold increase in invasion compared to the control strain. These data support the hypothesis that the *H. ducreyi* hemolysin is important in the pathogenesis of chancroid and may contribute to ulcer formation, invasion of epithelial cells, and evasion of the immune response.**

Haemophilus ducreyi is a gram-negative bacterium that causes the sexually transmitted genital ulcer disease chancroid. Chancroid ulcers are painful and can persist for several months if untreated, exposing the patient to secondary infections (20). Inguinal lymphadenopathy occurs in up to 50% of chancroid patients (20), and chancroid ulcers have been associated with increased heterosexual transmission of human immunodeficiency virus (6, 25, 45). Chancroid is most common in developing countries, although outbreaks occur in the United States, especially among individuals of lower socioeconomic status (43). Diagnosis of chancroid can be difficult since ulcers often resemble those of syphilis or herpes and isolation of *H. ducreyi* from lesions is frequently unsuccessful (43). For these reasons, the incidence of chancroid is probably higher than is currently recognized.

The initiation and progression of chancroid lesions has been studied by using human and animal models of chancroid (28, 34, 35, 40, 43). Three to ten days after inoculation with *H. ducreyi*, a papule develops, which either resolves or progresses to form a pustule. The pustule eventually ulcerates and involves cells of both the epidermis and the dermis (20). Histopathological analysis demonstrates that typical chancroid lesions consist of a deep necrotic ulcer containing disintegrating epithelial cells (20) and an infiltrate of polymorphonuclear leukocytes (PMNs), Langerhans' cells, macrophages, and CD4+ T cells (34, 35). Despite the presence of these inflammatory cells, the lesions persist if untreated and viable *H. ducreyi* can be recovered. Several potential virulence factors, including lipooligosaccharide (7), cytolethal distending toxin (9, 29), fine tangled pili (5), and a cell-associated hemolysin (22, 41), have been identified, although their contribution to the pathogenesis of chancroid is not well understood.

Expression of the cell-associated hemolysin of *H. ducreyi* requires two adjacent genes, *hhdB* and *hhdA* (23), which are

similar to the hemolysins of *Serratia marcescens*, *Edwardsiella tarda*, and *Proteus mirabilis* (23, 27, 44). The *S. marcescens* hemolysin, encoded by *shlB* and *shlA*, is the most thoroughly characterized of this group of hemolysins. ShlB is an outer membrane protein, which is required for secretion and activation of the hemolysin structural protein, ShlA (4, 32). Once secreted, ShlA interacts with target cell membranes, oligomerizes, and forms pores 2.5 to 3.0 nm in diameter, which lyse the target cell (33).

The effect of the *H. ducreyi* hemolysin on some human cell types has been previously examined (2, 21). These studies demonstrated the cytotoxic effect of the *H. ducreyi* hemolysin on human foreskin fibroblasts (HFFs) by using *H. ducreyi* 35000 and isogenic transposon mutants with insertions in *hhdB* (2, 11, 21). In the present study, we examined the range of cell types with which the hemolysin can interact by using a mutant with a deletion in *hhdA* and cloned hemolysin genes expressing different amounts of hemolysin. We found that in addition to its action on erythrocytes (RBCs) and HFFs, the hemolysin can lyse other cell types relevant to chancroid including human foreskin epithelial cells (HFEs) and immune system cells such as macrophages, T cells and B cells. In addition, we found that hemolysin enhances the invasion of HEp-2 epithelial cells. These results are consistent with a role for hemolysin in tissue destruction and/or immune system avoidance in chancroid ulcers.

MATERIALS AND METHODS

Bacterial strains and plasmids. The bacterial strains and plasmids used in this study are described in Table 1 and Fig. 1. Human cell lines were obtained from the American Type Culture Collection (Manassas, Va.).

Media and growth conditions. *H. ducreyi* strains were maintained as frozen suspensions in 50% glycerol at -70°C and cultured on chocolate agar with enrichment (PML Microbiologicals, Wilsonville, Oreg.) at 35°C in candle jars for 48 h. Liquid cultures were grown aerobically in Hd broth (42) at 35°C with shaking for 16 to 20 h. Mid-logarithmic-phase cultures were prepared by diluting overnight cultures 1:5 in fresh Hd broth and incubating them for 4 to 5 h with shaking at 35°C . Antibiotic concentrations for *H. ducreyi* were 50 μg of streptomycin per ml, 1 to 2 μg of chloramphenicol per ml, and 10 μg of ampicillin per ml. *Escherichia coli* and *Salmonella typhimurium* cultures were grown in Luria-Bertani (LB) broth or on LB agar plates (31) supplemented, when appropriate,

* Corresponding author. Mailing address: Division of Infectious Diseases, Box 359779, Harborview Medical Center, 325 Ninth Ave., Seattle, WA 98104. Phone: (206) 731-4926. Fax: (206) 731-8752. E-mail: patotten@u.washington.edu.

TABLE 1. Bacterial strains and plasmids used in this study

Bacterial strain or plasmid	Relevant characteristics	Reference or source
Strains		
<i>E. coli</i> HB101	Noninvasive strain, negative control	18
<i>S. typhimurium</i> SL1344	Highly invasive strain, positive control	16
<i>H. influenzae</i> Rd	Nonhemolytic, noncytotoxic, negative control, ATCC 33391	M. Roberts, University of Washington
<i>H. ducreyi</i>		
35000	Wild type, hemolytic	41
35000ΔAPC	35000 <i>hhdA::cat</i> , nonhemolytic, Cm ^r	This study
Plasmids		
pPT376	pUC19 with <i>hhdA</i> , Ap ^r	41
pBluescript KS(-)	Cloning vector, Ap ^r	Stratagene
pBluescript SK(-)	Cloning vector, Ap ^r	Stratagene
pPT376KS	<i>hhdA</i> on pBluescript, Ap ^r	This study
pPT376ΔPst	pPT376KS with internal <i>hhdA</i> <i>Pst</i> I fragment replaced with <i>Bam</i> HI linkers, Ap ^r	This study
pUC-ΔEcat	Source of <i>cat</i> cassette, Cm ^r	B. Green, Lederle-Praxis, Rochester, N.Y. (13)
pPT376ΔPstCm	pPT376ΔPst with <i>hhdA::cat</i> , Ap ^r Cm ^r	This study
pLS88	<i>H. ducreyi</i> shuttle vector, Km ^r Sm ^r	48
pBFD	Deletion derivative of pLS88, Sm ^r	This study
pCR2.1	TA cloning vector, Ap ^r Km ^r	Invitrogen, San Diego, Calif.
pLSSK	<i>H. ducreyi</i> shuttle vector, Sm ^r	This study
pLSKS	<i>H. ducreyi</i> shuttle vector, Sm ^r	This study
pBABN	<i>hhdBA</i> on pUC19	11
pLSBA+	<i>hhdBA</i> on pLSSK, Sm ^r	This study
pLSBA+2	<i>hhdBA</i> on pLSSK in same orientation as <i>lac</i> promoter, Sm ^r	This study
pLSBAHis	<i>hhdBA</i> fused to His tag on pLSSK	11
pLSB+	pLSSK with <i>hhdB</i> in same orientation as <i>lac</i> promoter, Sm ^r	This study
pPT384-TZ18	pTZ18R with <i>hhdBA</i> in same orientation as <i>lac</i> promoter, Ap ^r	41
pLS384-	<i>hhdBA</i> insert of pPT384-TZ18 in pLSKS opposite the <i>lac</i> promoter, Sm ^r	This study
pLS384-2	<i>hhdBA</i> on pLSSK in opposite orientation of <i>lac</i> promoter, Sm ^r	This study
pLS376-	<i>hhdA</i> on pLSSK in opposite orientation of <i>lac</i> promoter, Sm ^r	This study

with 100 μg of streptomycin per ml, 30 μg of chloramphenicol per ml, or 100 μg of ampicillin per ml.

Manipulation of DNA. Standard techniques were used for the isolation and manipulation of plasmid and chromosomal DNA (31). Restriction enzymes, T4 DNA ligase, T4 DNA polymerase, and oligonucleotide primers were purchased from Gibco BRL Life Technologies (Gaithersburg, Md.); deoxynucleoside triphosphates (dNTPs) were purchased from Promega (Madison, Wis.).

Construction of an isogenic, hemolysin-deficient *H. ducreyi* mutant. Strain 35000ΔAPC, a hemolysin-deficient mutant of strain 35000, was constructed as follows. First, the 5.2-kb *Sst*I-*Sal*I insert of pPT376 (41) containing part of *hhdB* and all of *hhdA* was cloned into pBluescript KS(-) (Stratagene). The resulting plasmid, pPT376KS, was digested with *Pst*I to delete a 2.6-kb internal fragment of *hhdA*, treated with T4 DNA polymerase to produce blunt ends, and then ligated to *Bam*HI linkers (Promega), creating pPT376ΔPst. The 1.2-kb *Bam*HI fragment of pUC-ΔEcat containing the chloramphenicol acetyltransferase (*cat*) gene was then cloned into the *Bam*HI site of pPT376ΔPst to produce pPT376ΔPstCm. Thus, the *hhdA::cat* construct on pPT376ΔPstCm expresses only the first 182 amino acids of HhdA. Plasmid pPT376ΔPstCm was introduced into wild-type *H. ducreyi* 35000 by electroporation, and transformants were selected on charcoal agar plates containing 1 μg of chloramphenicol per ml. A total of 23 transformants were obtained, of which 10 were nonhemolytic on bilayer horse blood agar plates (41). Of the 10 nonhemolytic transformants, 7 were subjected to analysis by PCR with primers A start and rev A end (Table 2) under the following conditions: 2 min at 92°C, followed by 30 cycles of 45 s at 92°C, 1 min at 63°C, and 5 min at 68°C, and ending with 7 min at 68°C, in a reaction mixture containing 50 mM Tris (pH 9.2), 16 mM (NH₄)₂SO₄, 5 mM MgCl₂, 0.5 mM total dNTPs, 0.3 μM (each) primer, and 2.5 U of Long Extend Polymerase (Boehringer Mannheim, Indianapolis, Ind.). A 3.6-kb PCR product was amplified from wild-type *hhdA*, while a product of 2.2 kb was obtained for the *hhdA::cat* allele. PCR products of 3.6 and 2.2 kb were amplified from six of the seven clones tested, indicating that they resulted from single crossovers and contained both wild-type *hhdA* and *hhdA::cat*; these were discarded. A single product of 2.2 kb was amplified from the seventh clone, indicating replacement

of wild-type *hhdA* with the *hhdA::cat* allele. This clone was named 35000ΔAPC and was subjected to Southern blot analysis, which confirmed deletion of the wild-type *hhdA* allele (data not shown). 35000ΔAPC is nonhemolytic both on bilayer horse blood agar plates and in liquid hemolysin assays and can be complemented with *hhdA* (data not shown).

Construction of pLSSK and pLSKS. Plasmids pLSSK and pLSKS, derivatives of pLS88 (48), were constructed as described below and in Fig. 2. First, a 3-kb PCR product was amplified from pLS88 with primers 88R and 88BFD (Table 2) under the following conditions: 3 min at 94°C, followed by 30 cycles of 1 min at 94°C, 1 min at 55°C, and 1 min at 72°C, and ending with 10 min at 72°C, in a reaction mixture containing 2.5 mM MgCl₂, 10 mM Tris (pH 8.3), 50 mM KCl, 0.5 mM (total) dNTPs, 0.36 μM (each) primer, and 0.5 U of *Taq* polymerase (Sigma, St. Louis, Mo.). The PCR product was digested with *Bgl*II and self-ligated to form plasmid pBFD. pBFD thus contains the origin of replication and genes for streptomycin and sulfonamide resistance. Next, the *lacZα* gene and the multiple-cloning site of pBluescript SK(-) (Stratagene) were PCR amplified with primers 5'BlueMCS and 3'BlueMCS (Table 2) under the conditions described above, except that 5 mM MgCl₂ and 0.10 μM primers were used. This 441-bp PCR product was cloned into pCR2.1 with the TA cloning kit as specified by the manufacturer (Invitrogen). The resulting plasmid was digested with *Bcl*I and ligated into the *Bgl*III site of pBFD, generating pLSSK. Plasmid pLSKS was constructed similarly, except that the *lacZα* gene and multiple-cloning site was amplified from pBluescript KS(-). Therefore, pLSKS is identical to pLSSK, except that the multiple-cloning site is reversed. Both pLSSK and pLSKS are similar to pLS88 in that they encode streptomycin and sulfonamide resistance and replicate in both *E. coli* and *H. ducreyi*; however, they have the additional advantages that they are smaller, contain a multiple-cloning site, and allow blue-white color selection in *E. coli*.

Construction of hemolysin-encoding plasmids. The plasmids used in this study are shown in Table 1 and Fig. 1, and their construction is described below. Plasmid pLSBA+2 was derived from pBABN, whose construction is described elsewhere (11). Briefly, pBABN carries *hhdBA*, wherein *hhdB* has been altered so that it has the *E. coli* consensus ribosome binding site and *hhdA* lacks the




FIG. 1. Plasmids used in this study and their hemolytic activities in 35000ΔAPC. *, data is expressed as a percentage of the hemolytic activity of strain 35000; the mean of a typical experiment performed in duplicate is shown with standard error. The experiment was repeated at least three times with similar results. The hemolytic activities of 35000ΔAPC and 35000ΔAPC(pLSSK) were 0.13% ± 0.00% and 0.66% ± 0.52%, respectively. B, *Bgl*II; D, *Dra*III; F, *Fsp*I; H, *Hind*III; Hp, *Hpa*I; N, *Nco*I; P, *Pst*I.

native stop codon. The entire 5.2-kb fragment was cloned into the *Bam*HI-*Sal*I sites of pLSSK so that transcription proceeds from the vector-encoded *lac* promoter. The resulting plasmid was named pLSBA+. To restore the native stop codon to *hhdA* on pLSBA+, a 334-bp PCR product was amplified from *H. ducreyi* 35000 chromosomal DNA with primers *Nco*F and A end *Sal* (Table 2) under the following conditions: 2 min at 94°C, followed by 30 cycles of 1 min at 94°C, 1 min at 55°C, and 2 min at 72°C, and ending with 7 min at 72°C, in a reaction mixture containing 50 mM Tris (pH 9.2), 16 mM (NH₄)₂SO₄, 5 mM MgCl₂, 0.5 mM (total) dNTPs, 0.3 μM (each) primer, and 2.5 U of *Taq* DNA polymerase (Promega). This 334-bp product was sequenced to confirm that no mutations had been introduced during amplification (data not shown), digested with *Hpa*I and *Sal*I, and used to replace the corresponding fragment of pLSBA+ (the *Hpa*I site is within the PCR fragment). The resulting plasmid, named

pLSBA+2 (Fig. 1), contains *hhdBA* and 167 bp of DNA downstream of the *hhdA* stop codon. Since pLSBA+2 lacks sequence upstream of *hhdBA*, expression proceeds from the vector-encoded *lac* promoter.

Plasmid pLSB+ (Fig. 1) was derived from pLSBAHis (11). Plasmid pLSBAHis was digested with *Hind*III and then religated to form pLSB+. Thus, pLSB+ contains *hhdB* expressed from the vector-encoded *lac* promoter and an *E. coli* consensus ribosome binding site, and the first 290 bp of *hhdA* on pLSSK.

pLS384-2 (Fig. 1) is identical to pLSBA+2, except that it contains the region 5' to *hhdB*, which is believed to contain the *hhdB* promoter and has the native ribosome binding site (23). pLS384-2 was constructed from pLS384- (not shown), which contains the 7.0-kb *Sma*I-*Sal*I fragment of pPT384-TZ18 (41) in pLSSK. pLS384- thus carries ~1.0 kb of DNA downstream of *hhdA*. To delete this downstream DNA, the 3' *Hpa*I-*Sal*I fragment of pLS384- was replaced with

TABLE 2. Primers used in this study

Primer name	Sequence ^a	Nucleotide recognition site (accession no.)
A start	5'- <u>gga tcc</u> aaG GAG ATA CAT ATA TGA AAA AAT GGA-3'	1885-1909 (U32175)
rev A end	5'- <u>gtc gac</u> TCG AAT GGC CAT CTT AGC ATC GAC-3'	5398-5421 (U32175)
88R	5'-aga tca <u>aga tct</u> GCA ATG CAA GGT CGC CAA CAC-3'	2991-3010 (L23118)
88BFD	5'-aga tca <u>aga tct</u> CTG CCG CAC AGC TCC ATA GG-3'	4711-4730 (L23118)
5'BlueMCS	5'-gat <u>gat cAG</u> CGG ATA ACA ATT TCA CAC AGG-3'	827-846 (X52324)
3'BlueMCS	5'-gat <u>gat cAC</u> GCT TAC AAT TTC CAT TCG C-3'	451-470 (X52324)
<i>Nco</i> F	5'-ATG CAA ATG GTA TAA AAG TTA G-3'	5077-5099 (U32175)
A end <i>Sal</i>	5'- <u>gtc gac</u> CCA CTT ACA TCA ATC-3'	5576-5591 (U32175)

^a Primer sequences homologous to the template are shown in capital letters, non-homologous sequences are in lowercase letters, and restriction sites incorporated into primers to facilitate the cloning of PCR products are underlined.




FIG. 2. Construction of pLSSK and pLSKS. pLSSK carries streptomycin resistance, sulfonamide resistance, *lacZα*, and the multiple-cloning site of pBluescript SK(-). Plasmid pLSKS contains the multiple-cloning site of pBluescript KS(-) and is therefore identical to pLSSK, except that the multiple-cloning site is reversed in *lacZα*. Details of the construction are described in Materials and Methods. Asterisks mark restriction sites in the multiple-cloning site (MCS) that are not unique.

a smaller, PCR-amplified fragment containing only 167 bp of DNA downstream of *hhdA* in the same manner as described above for pLSBA+2. The resulting plasmid was named pLS384-2.

pLS376- was constructed by cloning the 5.8-kb *SalI-SmaI* fragment of pPT376 (41) into pLSKS. pLS376- thus contains the C-terminal 470 bp of *hhdB* and the full-length *hhdA* genes transcribed opposite the vector-encoded *lac* promoter.

Liquid hemolysin assays. Quantitative hemolysin assays were performed on logarithmic-phase cultures (1.5 ml), which were microcentrifuged for 1 min and then resuspended in 1 ml of 0.85% NaCl-10 mM CaCl₂. Serial twofold dilutions were made in 96-well round-bottom plates in the same buffer, and washed horse RBCs (ca. 1% [wt/vol]) were added to each well. After a 1-h incubation at 37°C, the plate was centrifuged for 10 min at 500 × *g*, 100 μl of the supernatant was removed, and the absorbance at 540 nm was determined. All hemolytic values are the average of duplicate samples and represent the dilution of the test culture (at OD₅₄₀ = 1.0) that lyses 50% of the RBCs. This hemolytic activity was determined by using the following equation: hemolytic activity = percent lysis / (50 × OD₅₄₀ × *D*). Percent lysis was determined by comparison to RBCs lysed with distilled water (total lysis), OD₅₄₀ is the optical density of the test culture at 540 nm, and *D* is the dilution of the test culture. The hemolytic activity of the strains varied from experiment to experiment (up to threefold), but the relative

amounts of hemolytic activity were consistent between strains within experiments.

Cell culture. HEp-2 (ATCC CCL-23), U937 (ATCC CRL-1593), Daudi (ATCC CCL-213), Jurkat (ATCC TIB-152), and Raji (ATCC CCL-86) cells were cultured, at 37°C in a humidified atmosphere of 5% CO₂ and 95% air, in RPMI 1640 medium supplemented with glutamine (ICN Biomedicals, Inc., Aurora, Ohio), sodium bicarbonate (Sigma), and 10% fetal bovine serum (Gibco BRL Life Technologies). Primary cultures of HFEs and HFFs were obtained as previously described (3) and maintained in keratinocyte serum-free medium (KFSM; Gibco BRL Life Technologies) or RPMI 1640 medium, respectively. Twice weekly, HEp-2, HFF, or HFE monolayers were treated with a solution of trypsin-EDTA (Gibco BRL Life Technologies) to produce a single-cell suspension and then plated at a dilution of 1:20 in fresh medium. U937, Daudi, Jurkat, and Raji cells were also split twice weekly by being diluted 1:20 in fresh medium. To induce adherence, U937 cells were treated for 24 h with 250 ng of phorbol myristate acetate (Sigma) per ml of culture medium. Adherent U937 cells were washed once with balanced salt solution, scraped into culture medium with a glass rod, washed once in fresh culture medium, and then used in the cytotoxicity assay as described below.

Isolation of monocytes and PMNs from human blood. Fresh venous blood (30 ml) from healthy volunteers was collected in EDTA-treated tubes and immediately processed for isolation of mononuclear cells and PMNs in using MonoPoly Resolving Medium (ICN Biomedicals, Inc.) as specified by the manufacturer. Purified cells were stained to confirm morphology by using the Diff-Quik stain set (Dade Diagnostics, Aguada, P.R.). PMN preparations consisted of >99% PMNs; mononuclear cell preparations were mixtures of monocytes, lymphocytes, and platelets. Cells were used in cytotoxicity assays immediately after isolation.

Cytotoxicity assays. Approximately 4 h before each assay, 2×10^4 (HEp-2, HFF, and HFE) or 5×10^4 (U937, Daudi, Raji, Jurkat, mononuclear cells, and PMNs) cells were plated in 96-well flat-bottom plates in RPMI 1640 medium–1% fetal bovine serum or KSMF as appropriate. Overnight cultures of *H. ducreyi* strains were diluted 1:5 in Hd broth (42) and incubated at 35°C for 5 h with shaking. These bacterial samples (1.5 ml) were microcentrifuged for 1 min and then resuspended in RPMI 1640 medium–1% fetal bovine serum or KSMF (1 ml); the culture densities were similar between experiments. Dilutions (1:5 to 1:500) of each bacterial sample were made, and 100 μ l was added to quadruplicate wells. The plate was centrifuged for 10 min at $150 \times g$ and then incubated at 37°C in humidified 5% CO₂–95% air for 3 h. A 50- μ l volume of the supernatant was tested for lactate dehydrogenase (LDH) activity by the CytoTox 96 nonradioactive cytotoxicity assay (Promega) as specified by the manufacturer. The normalized LDH activity was calculated in the same manner as the hemolytic activities described above. Complete lysis of target cells for controls was achieved by freezing and thawing (HEp-2 cells) or treatment with Triton X-100 (all other cell types). Liquid hemolysis assays were performed on test bacterial cultures at the same time as the cytotoxicity assays.

Invasion and adherence assays. HEp-2 cells were seeded into 24-well plates at a density of 5×10^5 to 1×10^6 cells per well and incubated for 16 to 20 h. Overnight cultures of *H. ducreyi* were diluted 1:5 in Hd broth and incubated with shaking for 4 to 5 h at 35°C. The cultures were then microcentrifuged for 1 min and resuspended in cell culture medium to an approximate OD₅₄₀ of 1.0. Overnight cultures of *E. coli* HB101 were diluted 1:200 in LB broth and grown with shaking at 35°C. *S. typhimurium* SL1344 was grown overnight in LB broth at 37°C without shaking and then diluted 1:25 in LB broth and incubated for 4 to 5 h without shaking. SL1344 and HB101 were microcentrifuged for 1 min and then resuspended in culture medium to an approximate OD₅₄₀ of 0.1. Each bacterial suspension was then diluted 1:10 in culture medium, and 100 μ l of this dilution was added to triplicate wells of HEp-2 cells. The plate was centrifuged for 10 min at $150 \times g$ and then incubated at 37°C in humidified 5% CO₂–95% air for 1 h. The wells were washed three times with warm phosphate-buffered saline and then incubated for 1 h with 1 ml of culture medium containing 30 μ g of gentamicin. Three washes with phosphate-buffered saline were performed, and then HEp-2 cells were lysed with trypsin-EDTA. Released bacteria were diluted in LB broth and plated on chocolate agar (*H. ducreyi*) or LB agar (HB101 and SL1344). All strains were similar in their sensitivity to gentamicin (data not shown).

Adherence of *H. ducreyi* strains to HEp-2 cells was measured as previously described (39), except that adherence was measured after a 90-min incubation.

Statistical methods. Student's *t* distribution was used to determine *P* values for differences between sample means (37).

RESULTS

Development of the cytotoxicity assay. The goal of this study was to determine the target cell range of the *H. ducreyi* cell-associated hemolysin. However, previous studies have suggested that the target cell range of the secreted cytolethal distending toxin might overlap that of the hemolysin, making it difficult to determine the contribution of each toxin separately (21). Since hemolysin is poorly expressed in *E. coli* (11), we developed an assay to measure cytotoxicity in *H. ducreyi*, which would minimize the possible effects of the cytolethal distending toxin or other unidentified toxins. In this assay, *H. ducreyi* cultures were grown to the mid-logarithmic phase to induce hemolysin expression, the bacterial cells were washed to reduce the amount of secreted cytolethal distending toxin introduced into the assay mixture, and LDH activity was measured after only 3 h of coinubation with target cells. Initial experiments to evaluate this assay were performed with HFFs since previous studies have shown that the hemolysin is cytotoxic to these cells (2, 21). To confirm these observations, we constructed a mutant of *H. ducreyi* 35000 by replacing *hhdA* with *hhdA::cat* via allelic exchange (see Materials and Methods and Fig. 1). The resulting mutant was named 35000 Δ APC and is nonhemolytic both on bilayer horse blood agar plates and in liquid hemolysin assays (data not shown). Cytotoxicity assays with these strains demonstrated that strain 35000 caused the




FIG. 3. Hemolysin is cytotoxic to HFFs. *H. ducreyi* strains (ca. 5×10^7 CFU) were incubated with HFFs (2×10^4) for 3 h, and the LDH activity present in culture supernatants was measured. For each strain, the mean of a typical experiment performed in triplicate is shown with standard errors. The experiment was repeated at least three times with similar results.

release of approximately 5% of the total cellular LDH from HFFs while 35000 Δ APC caused the release of only 1% of the LDH (Fig. 3), confirming previous observations that hemolysin is a fibroblast contact cytotoxin (2, 21). While this difference was statistically significant ($P < 0.001$), the low levels of LDH released suggested that this assay may be insufficiently sensitive to detect the activity of hemolysin on other cell types.

To improve the sensitivity of the cytotoxicity assay, we sought ways to increase hemolysin expression by *H. ducreyi*. Hemolysin expression in other organisms (e.g., *E. tarda* [15] and *S. marcescens* [26]) is increased when the iron concentration in the culture medium is reduced. We had previously shown that hemolysin expression was optimal in the logarithmic phase in Hd broth (41), but the complex nature of this and other media for growth of *H. ducreyi* limits our ability to control the amount of iron and other nutrients which might affect hemolysin expression. As an alternative, we constructed plasmids from which cloned hemolysin genes were expressed. This was facilitated by the construction of a pair of *H. ducreyi* shuttle vectors (pLSSK and pLSKS) that were derived from pLS88 (Fig. 2). These vectors are smaller than pLS88, contain a multiple-cloning site, and allow blue-white screening in *E. coli* (Fig. 2). Using these cloning vectors, we constructed pLSBA+2 and pLS384-2, which express ca. 20- to 80-fold more hemolytic activity than strain 35000 does (Fig. 1). Both plasmids carry full-length *hhdBA* but differ in their upstream sequences: pLS384-2 extends 704 bp upstream of *hhdB*, a region believed to contain the promoter (23, 41), while pLSBA+2 expresses *hhdBA* from the vector-encoded *lac* promoter (Fig. 1).

Strain 35000 Δ APC with the hemolysin-expressing plasmids pLSBA+2 or pLS384-2 caused the release of large amounts of LDH ($\geq 100\%$ compared to lysis by Triton X-100) from HFFs, substantially more than that released by the control consisting of vector alone [35000 Δ APC(pLSSK)] (Fig. 3). Thus, a short




FIG. 4. Dose-dependent lysis of RBCs and HFFs by hemolysin-producing *H. ducreyi*. Symbols: Δ , 35000 Δ APC(pLS384-2) versus RBCs; \blacktriangle , 35000 Δ APC(pLS384-2) versus HFFs; \circ , 35000 Δ APC(pLSBA+2) versus RBCs; \bullet , 35000 Δ APC(pLSBA+2) versus HFFs; \square , 35000 versus RBCs; \blacksquare , 35000 versus HFFs. Dilutions of the strains indicated were made and incubated with washed horse RBCs or HFFs for 1 or 3 h, respectively. The percent lysis of RBCs and HFFs was determined as described in Materials and Methods. 35000 Δ APC(pLSSK) was not cytotoxic or hemolytic at any of the dilutions tested (data not shown). For each combination, the mean of a typical experiment is shown with standard errors. Hemolysis was measured in duplicate; LDH release was measured in triplicate. Three repetitions yielded similar results.

(3-h) coincubation of *H. ducreyi* strains expressing cloned hemolysin genes with HFFs was cytotoxic, similar to results obtained with wild-type hemolysin expression and long incubation times (24 h) (2, 21). To rule out the possibility that HhdB caused the observed cytotoxicity, we constructed a plasmid (pLSB+, Fig. 1) which carries only *hhdB*. As expected, 35000 Δ APC(pLSB+) was neither hemolytic (Fig. 1) nor cytotoxic, causing the release of <1% of the LDH, comparable to the control 35000 Δ APC(pLSSK) (Fig. 3). In contrast, pLS376-, which carries only *hhdA*, expressed ca. 40% of the hemolytic activity of the wild-type strain 35000 (Fig. 1) and restored a corresponding level of cytotoxicity to 35000 Δ APC (Fig. 3). Because the levels of hemolytic activity and cytotoxicity were very low for this strain, 35000 Δ APC(pLS376-) was excluded from further cytotoxicity assays.

To determine if LDH release correlated with hemolytic activity, dose-response experiments were performed with 35000 Δ APC(pLSBA+2) and 35000 Δ APC(pLS384-2) compared to the wild-type strain 35000 (Fig. 4). In these experiments, lysis of HFFs paralleled lysis of RBCs for 35000 Δ APC(pLSBA+2) and 35000 Δ APC(pLS384-2) at all bacterial cell concentrations, demonstrating a correlation between hemolytic activity and cytotoxicity. These experiments also demonstrated that horse RBCs are more sensitive than HFFs to lysis by hemolysin-producing *H. ducreyi* strains even though hemolysis was measured after only a 1-h incubation whereas LDH release was measured after a 3-h incubation. This difference was not due to the different buffers used for the cytotoxicity and hemolysin assays, since the hemolytic activity of the strains was similar in both media (data not shown). Strain 35000 was not as cytotoxic as expected from its hemolytic activity, perhaps suggesting that (i) a threshold number of hemolysin molecules are needed to lyse HFFs, (ii) HFFs are able to repair damage caused by the lower levels of hemolysin, or (iii) inhibition or

TABLE 3. *H. ducreyi* hemolysin is cytotoxic to fibroblasts and human epithelial cells

Strain	Normalized LDH release ^a from:		
	HFF	HFE	HEp-2 cells
35000	0.08 \pm 0.00	0.20 \pm 0.01	0.10 \pm 0.01
35000 Δ APC	0.02 \pm 0.01	0.18 \pm 0.03	0.05 \pm 0.01
35000 Δ APC(pLSSK)	0.02 \pm 0.00	0.17 \pm 0.01	0.05 \pm 0.01
35000 Δ APC(pLSBA+2)	19.25 \pm 3.49	28.37 \pm 8.69	2.74 \pm 0.20
35000 Δ APC(pLS384-2)	59.78 \pm 2.85	88.70 \pm 13.46	3.98 \pm 0.25
35000 Δ APC(pLSB+)	0.01 \pm 0.00	0.14 \pm 0.04	0.08 \pm 0.04
35000 Δ APC(pLS376-)	0.04 \pm 0.00	ND ^b	ND

^a Values represent normalized LDH release (see Materials and Methods) and are the average of quadruplicate samples (HFFs were assayed in triplicate) \pm standard error. The results of a typical experiment are shown; the experiment was repeated at least three times with similar results.

^b N.D., not determined.

degradation of hemolysin by other cellular factors can be overcome with higher levels of hemolysin.

***H. ducreyi* hemolysin is cytotoxic for human epithelial cells.** Our cytotoxicity assay with strains expressing cloned hemolysin genes and short incubation times was consistent with previous results showing that wild-type levels of hemolysin are cytotoxic to HFFs after a 24-h cocultivation (2, 21). We therefore expanded our analysis of the target cell range of hemolysin to other epidermal cells including a human epithelial cell line (HEp-2) and primary cultures of HFEs (Table 3). To compare the relative cytotoxicity between experiments and cell types, LDH release was adjusted to 50% and corrected for slight differences in the turbidity of test cultures (normalized LDH release [see Materials and Methods]). For comparison, the data demonstrating cytotoxicity of hemolysin for HFFs (Fig. 3) are recalculated and presented in Table 3 as normalized LDH release. In these experiments, HFEs and HEp-2 cells were lysed by 35000 Δ APC(pLSBA+2) or 35000 Δ APC(pLS384-2) but not by 35000 Δ APC(pLSSK), similar to the results with HFFs. Strain 35000 did not cause significant cytotoxicity for HFEs or HEp-2 cells in this assay with short incubation times. Significantly, 35000 Δ APC and 35000 Δ APC(pLSSK) were not cytotoxic in these assays, indicating that LDH release due to other *H. ducreyi* products including cytolethal distending toxin was not significant in our assay, even though the cytolethal distending toxin acts on HEp-2 cells during extended incubations (9, 29). As expected, 35000 Δ APC complemented with *hhdB* alone (pLSB+) was not cytotoxic.

***H. ducreyi* hemolysin lyses human immune system cells.** We next assessed the ability of the *H. ducreyi* hemolysin to lyse human immune system cells by using both cells freshly isolated from human blood and several immune system cell lines. Human PMNs and mononuclear cells were separated by density gradient centrifugation and analyzed for their susceptibility to hemolysin (Table 4). In these experiments, cytotoxicity attributable to hemolysin was observed in the mononuclear cell fraction, which contained monocytes, lymphocytes, and platelets. Both 35000 Δ APC(pLSBA+2) and 35000 Δ APC(pLS384-2) were cytotoxic with normalized LDH values of 1.52 and 44.53, respectively, consistent with their relative hemolytic activities. As expected, 35000 Δ APC, 35000 Δ APC(pLSB+), and 35000 Δ APC(pLSSK) were not cytotoxic and the amount of hemolysin produced by strain 35000 in these experiments was not sufficient to cause cytotoxicity to mononuclear cells (Table 4). In contrast to the results seen with mononuclear cells, the low levels of LDH released from PMNs incubated with 35000 Δ APC(pLSBA+2) and 35000 Δ APC(pLS384-2) sug-

TABLE 4. *H. ducreyi* hemolysin is cytotoxic to mononuclear cells but not PMNs

Strain	Normalized LDH release ^a from:	
	Mononuclear cells	PMNs
35000	0.00 ± 0.02	0.26 ± 0.22
35000ΔAPC	0.12 ± 0.03	0.41 ± 0.06
35000ΔAPC(pLSSK)	0.00 ± 0.11	0.32 ± 0.25
35000ΔAPC(pLSBA+2)	1.52 ± 0.11	0.18 ± 0.20
35000ΔAPC(pLS384-2)	44.53 ± 4.46	0.85 ± 0.14
35000ΔAPC(pLSB+)	0.00 ± 0.25	0.15 ± 0.22

^a Values represent normalized LDH release and are the average of quadruplicate samples ± standard error. The results of a typical experiment are shown; the experiment was repeated twice with mononuclear cells and three times with PMNs with similar results.

gested that this cell type is relatively insensitive to lysis by hemolysin under these experimental conditions (Table 4).

To expand the observation that *H. ducreyi* hemolysin lyses blood mononuclear cells, cytotoxicity assays were also performed with immune system cell lines including human macrophage-like cells (U937), T lymphocytes (Jurkat cells), and B lymphocytes (Daudi and Raji cells) (Table 5). In these experiments, U937 macrophage-like cells were lysed by 35000ΔAPC (pLSBA+2) and 35000ΔAPC(pLS384-2) but not by 35000ΔAPC with vector alone (pLSSK) or *hhdB* alone (pLSB+). The normalized LDH values for 35000ΔAPC(pLSBA+2) and 35000ΔAPC(pLS384-2) were 5.67 and 69.62, respectively, compared to 0.18 for 35000ΔAPC(pLSSK) ($P < 0.001$). The wild-type strain 35000 was only slightly cytotoxic (0.35 ± 0.05) for this cell line. Similar results were obtained with T lymphocytes (Jurkat cells), with hemolysin-expressing clones causing significantly more LDH release than the control with vector alone. Among the B-lymphocyte lines, Daudi cells were more sensitive to lysis by hemolysin than were Raji cells. Both cell lines released similar amounts of LDH after incubation with 35000ΔAPC(pLSBA+2). However, Daudi cells were ca. sevenfold more sensitive to lysis by 35000ΔAPC(pLS384-2) than Raji cells were. Both cell lines were minimally affected by the hemolysin levels produced by strain 35000.

Since hemolysin expression of the strains varied slightly between experiments, we determined the relative sensitivity of the cell types to hemolysin by calculating the ratio of hemolytic activity (data not shown) to normalized LDH (Table 6). For simplicity, this analysis was restricted to a single hemolysin-producing strain, 35000ΔAPC(pLS384-2). In this analysis, we found that T cells were the most sensitive to hemolysin-mediated lysis (i.e., had the lowest ratio of hemolytic activity to normalized LDH) followed by U937 macrophage-like cells, HFES, HFFs, and Daudi cells. Raji and HEp-2 cells were only

modestly affected by hemolysin, while PMNs were not lysed by any of the strains under these conditions.

***H. ducreyi* hemolysin enhances invasion of human epithelial cells.** Since *H. ducreyi* has previously been found to invade HEp-2 cells and HFES (39), we examined the role of hemolysin in invasion of HEp-2 cells by the hemolysin-deficient mutant, strains expressing cloned hemolysin genes, and strain 35000 (Fig. 5). Low multiplicities of infection (1 to 10 CFU per epithelial cell) and short incubation times (1 h) were used to minimize cytotoxicity to HEp-2 cells by the hemolysin. The highly invasive *S. typhimurium* SL1344 (16) and the noninvasive *E. coli* HB101 served as positive and negative controls, respectively. Invasion of HEp-2 cells by 35000 ranged from 0.25 to 0.95% of the inoculum, consistent with previous results (39). Invasion by 35000ΔAPC was not significantly different from invasion by 35000, 35000ΔAPC(pLSSK), or 35000ΔAPC(pLS376-). Similarly, invasion by strain 35000ΔAPC(pLSBA+2) was not significantly different from invasion by 35000 or 35000ΔAPC(pLSSK) ($P < 0.10$); however, 35000ΔAPC(pLS384-2) invaded significantly more than 35000 (pLSSK) ($P = 0.05$), at levels similar to those of SL1344. Coinfection experiments showed that 35000ΔAPC(pLS384-2) did not enhance uptake of HB101, suggesting that increases in invasion were specific to the bacterial cell producing hemolysin (data not shown). Furthermore, plasmid pLSB+ did not affect invasion by 35000ΔAPC, indicating that HhdB alone plays no direct role in the invasion of these cells (Fig. 5).

Hemolysin may enhance invasion simply by increasing the adherence of strains to cells and allowing other virulence factors better access to cell membranes. To examine this possibility, we measured the adherence of 35000, 35000ΔAPC, 35000ΔAPC(pLSSK), and 35000ΔAPC(pLS384-2) to HEp-2 cells and found that all four strains adhered at similar levels (data not shown). These results suggest that the hemolysin is not acting as an adhesin in these experiments but instead acts at a different step in the invasion process.

DISCUSSION

In this study, we found that the target cell range of the *H. ducreyi* cell-associated hemolysin includes T cells, macrophages, HFES, HFFs, and B cells. T cells and macrophages were the cell types most affected by hemolysin, followed by HFES, HFFs, B cells, and HEp-2 cells, while PMNs were relatively insensitive to lysis by hemolysin in our experiments. In addition, we showed that hemolysin expression enhances the invasion of *H. ducreyi* into HEp-2 cells and that this invasion is specific for *H. ducreyi*, since hemolysin-producing strains did not allow the invasion of *E. coli* in coinfection experiments.

In addition to expanding the cell range of hemolysin on clinically relevant cell types, our experiments differed in several

TABLE 5. *H. ducreyi* hemolysin is cytotoxic to human immune system cell lines

Strain	Normalized LDH release ^a from:			
	U937 cells	Jurkat cells	Daudi cells	Raji cells
35000	0.35 ± 0.05	1.08 ± 0.07	0.21 ± 0.01	0.12 ± 0.01
35000ΔAPC	0.08 ± 0.02	0.07 ± 0.00	0.09 ± 0.02	0.08 ± 0.01
35000ΔAPC(pLSSK)	0.18 ± 0.07	0.04 ± 0.01	0.06 ± 0.03	0.03 ± 0.02
35000ΔAPC(pLSBA+2)	5.67 ± 0.30	73.63 ± 2.83	1.91 ± 0.18	1.16 ± 0.19
35000ΔAPC(pLS384-2)	69.62 ± 10.42	225.95 ± 17.22	30.09 ± 0.12	4.23 ± 0.23
35000ΔAPC(pLSB+)	0.17 ± 0.04	0.02 ± 0.05	0.06 ± 0.02	0.06 ± 0.02

^a Values represent normalized LDH release and are the average of quadruplicate samples ± standard error. The results of a typical experiment are shown; the experiment was repeated at least three times with similar results.

TABLE 6. Ratios of hemolytic activity to normalized LDH release indicate relative sensitivity to lysis by hemolysin

Cell type	Ratio (hemolytic activity/nLDH) ^a
Jurkat	2.21
U937	4.85
HFE	5.63
HFF	13.40
Daudi	16.60
HEp-2	92.52
Raji	118.06

^a Ratios for 35000ΔAPC(pLS384-2) are shown for representative experiments. Hemolytic activities were determined in duplicate; normalized LDH release (nLDH) was determined in quadruplicate. Small numbers indicate relatively high sensitivity to lysis by hemolysin.

ways from previous studies showing the cytotoxicity of hemolysin for HFFs and HaCaT cells (2, 21). First, previous studies (2, 11, 21) used mutants with mutations in *hhdB* rather than *hhdA* to demonstrate differences in wild-type and hemolysin mutant activity. The *hhdA* gene encodes the hemolysin structural protein based on the hemolytic activity of purified HhdA (11) and the homology of *hhdA* to the *S. marcescens* *shlA* hemolysin gene (23, 27, 41). HhdB is probably involved in secretion and activation of HhdA, similar to its homologue, the *S. marcescens* *shlB* gene (4, 32). While HhdB activity may be specific to HhdA, it is also possible that this protein affects the secretion and/or activation of other, as yet unidentified, proteins of *H. ducreyi*. Second, we used quantitative LDH release assays, cloned hemolysin genes, and modified incubation conditions to analyze the effect of this cell-associated hemolysin and minimize the effect of the secreted cytolethal distending toxin (9, 29). We showed that the results of these short-term cytotoxicity assays, using strains expressing cloned hemolysin genes, mimic results obtained for HFFs with wild-type-hemolysin-expressing strains and long exposure times (2, 21). These modifications allowed us to determine the specificity of the hemolysin for many cell types important in chancroidal disease while avoiding the contaminating effects of other *H. ducreyi* toxins. We hypothesize that since macrophages, T cells, and HFEs were more sensitive than HFFs to overexpressed hemolysin, they are also likely targets for wild-type levels of hemolysin in the previously described cocultivation assay (2, 21). The interaction of hemolysin with B cells and HEp-2 cells needs to be studied further to determine if this level of sensitivity is relevant to wild-type hemolysin expression levels.

The target cell specificity of hemolysins (cytolysins) from other organisms is thought to partially define the host range and disease manifestation in the host. For example, the RTX leukotoxins LktA of *Pasteurella haemolytica* and AaltA of *Actinobacillus actinomycetemcomitans* lyse only ruminant or primate leukocytes, respectively, suggesting a role in attenuating the immune response to these organisms (47). However, other RTX hemolysins, including HlyA of *E. coli*, AppA of *Actinobacillus pleuropneumoniae*, and CyaA of *Bordetella pertussis*, have a broad target cell range including RBCs and nucleated cells from different species, suggesting a broader role in pathogenesis (47). The *Proteus mirabilis* hemolysin (*hpmBA*), which is homologous to the *H. ducreyi* hemolysin, has a broad cell target range which includes human bladder and renal epithelial cells, B cells, monocytes, and African green monkey kidney cells (8, 38). Similarly, the *H. ducreyi* hemolysin appears to have a broad target cell range, as demonstrated here and by previous work (22, 41), suggesting that the hemolysin is important in the interactions of *H. ducreyi* with many cell types in chancroidal

lesions. For example, hemolysin may contribute to ulcer formation by lysing keratinocytes or fibroblasts. Chancroid ulcers contain large numbers of T cells and macrophages, and yet viable *H. ducreyi* persists in these lesions (20). Our observation that T cells and macrophages are sensitive to hemolysin may suggest a role for hemolysin in inhibition of an effective cell-mediated immune response that clears the *H. ducreyi* infection. While the data presented here defines the target cell range of hemolysin and the relative sensitivity of the various cell types to hemolysin, further experiments are needed before we can determine the in vivo relevance of this target cell range, including the effect of hemolysin on virulence and survival of *H. ducreyi* in animal models and levels of hemolysin expression in chancroidal lesions. In addition, the nature of the different susceptibilities of the target cells, possibly based on differences in (i) membrane composition, (ii) hemolysin receptor expression, or (iii) the ability of the affected cell to repair membrane damage induced by the hemolysin, will also be interesting subjects of future research.

Although our experiments measured target cell lysis, the *H. ducreyi* hemolysin may also have other, more subtle effects on cells. Lysis may occur only where there are many hemolysin-producing bacteria per target cell or where hemolysin expression is high. *H. ducreyi* grows as microcolonies in the rabbit model of chancroid, suggesting that high bacterium-to-target-cell ratios can occur in vivo (28) and that hemolysin-mediated lysis of cells may occur in these areas of the lesion. In areas where there are few bacteria per target cell or where hemolysin expression is low, the hemolysin may alter cellular function rather than lyse the cell outright. Effects of sublytic concentrations of hemolysin have been documented with other bacteria, including the closely related *S. marcescens* hemolysin, which induces chemiluminescence in PMNs and stimulates the release of leukotriene B₄ (17). Streptolysin O of *Streptococcus pyogenes* induces interleukin-1β (IL-1β), IL-6, IL-8, and prostaglandin E₂ expression by keratinocytes (30), while the *E. coli* hemolysin increases the release of leukotrienes from PMNs and of IL-1β from monocytes and inhibits antigen processing




FIG. 5. *H. ducreyi* hemolysin enhances invasion of human epithelial cells. The strains indicated were tested for invasion by using a gentamicin protection assay at a multiplicity of infection of approximately 1 bacterium per epithelial cell. The data shown is from a single experiment performed in triplicate; bars indicate standard error. The experiment was repeated at least three times with similar results.

and presentation by murine macrophages (46). Further exploration of the effects of sublytic doses of hemolysin on cellular functions is needed to understand the contribution of the *H. ducreyi* hemolysin to pathogenesis.

Our experiments showing that strains with cloned hemolysin genes were clearly more invasive than strains containing vector alone suggests a role for hemolysin in invasion of epithelial cells. Other organisms including *Edwardsiella tarda*, *Shigella flexneri*, and *Listeria monocytogenes* produce hemolysins that enhance invasion by allowing cell entry into or escape from the phagocytic vacuole (10, 14, 36). We saw no significant difference in invasion by the wild-type and isogenic hemolysin mutant strains, perhaps reflecting the difficulty in demonstrating small losses in invasiveness for an organism in which only ca. 1% of the inoculum is internalized. Alternatively, the effect of deleting only one of many factors required for invasiveness may be difficult to measure. Other researchers have demonstrated that mutants defective in lipooligosaccharide biosynthesis are impaired in invasion of HFEs; however, this may simply be a consequence of their decreased adherence to these cells (12). This is not the case for hemolysin, since wild-type, mutant, and overexpressing strains adhered at similar levels to HEp-2 cells. Experiments on the regulation of hemolysin expression, expression levels of hemolysin in vivo, and the mechanism of invasion of *H. ducreyi* are needed to clarify the role of hemolysin in invasion of this organism.

While several researchers have confirmed invasion of epithelial cells by *H. ducreyi* (12, 39), invasion of fibroblasts is more controversial. Lammel et al. reported that *H. ducreyi* could be found within HFFs by transmission electron microscopy (19). However, Alfa et al. were unable to confirm this observation and further demonstrated lack of invasion of HFFs by *H. ducreyi* in a gentamicin protection assay (1). The fact that HFFs are sensitive targets for hemolysin may suggest that *H. ducreyi* lyses these cells, confounding identification of intracellular bacteria by microscopy and allowing an influx of gentamicin that kills intracellular bacteria. This is apparently the case with wild-type *P. mirabilis*, which expresses a hemolysin that lyses human renal epithelial cells, resulting in an apparent decrease in invasion compared to hemolysin-deficient mutants in gentamicin protection assays (8).

The in vivo role of the hemolysin in chancroid pathogenesis is still unclear in human and animal models of chancroid. Palmer et al. evaluated a hemolysin-deficient mutant in a human model of *H. ducreyi* infection and found that the mutant produced erythema and pustules similar to the wild-type parent; they concluded that hemolysin plays a minor role in early lesion development (24). However, this model does not fully mimic chancroidal disease, since later stages of infection (ulceration, immune system avoidance, and transmission) cannot be evaluated and inoculations are made on the upper arm, not on genital skin. In contrast, a role for hemolysin in survival in its only known niche, the human host, is suggested by the observations that (i) all strains of *H. ducreyi* express hemolysin in vitro; (ii) hemolysin is produced in vivo, since both humans and animals produce antibodies to HhdA after infection with *H. ducreyi* (11); and (iii) the target cell range of hemolysin includes clinically relevant cell types. Further studies evaluating the levels of hemolysin expression in vivo, the sublytic effects of hemolysin on target cells, and the effect of hemolysin on different animal models of chancroid are needed to clarify the contribution of hemolysin to the pathogenesis of human disease.

ACKNOWLEDGMENTS

This work was supported by grant AI33522 from the National Institutes of Health to P.A.T. G.E.W. is supported by NIH STD/AIDS Research Training Grant T32 AI07140.

We thank Steve Moseley, Stephen Lory, Derek Wood, and Rodney Welch for helpful discussions and critical review of the manuscript.

REFERENCES

- Alfa, M. J., P. DeGagne, and T. Hollyer. 1993. *Haemophilus ducreyi* adheres to but does not invade cultured human foreskin cells. *Infect. Immun.* **61**: 1735–1742.
- Alfa, M. J., P. DeGagne, and P. A. Totten. 1996. *Haemophilus ducreyi* hemolysin acts as a contact cytotoxin and damages human foreskin fibroblasts in cell culture. *Infect. Immun.* **64**:2349–2352.
- Blanton, R. A., T. S. Kupper, J. K. McDougall, and S. Dower. 1989. Regulation of interleukin 1 and its receptor in human keratinocytes. *Proc. Natl. Acad. Sci. USA* **86**:1273–1277.
- Braun, V., R. Ondraczek, and S. Hobbie. 1993. Activation and secretion of *Serratia* hemolysin. *Int. J. Med. Microbiol. Virol. Parasitol. Infect. Dis.* **278**: 306–315.
- Brentjens, R. J., M. Ketterer, M. A. Apicella, and S. M. Spinola. 1996. Fine tangled pili expressed by *Haemophilus ducreyi* are a novel class of pili. *J. Bacteriol.* **178**:808–816.
- Cameron, D. W., J. N. Simonsen, L. J. D'Costa, A. R. Ronald, G. M. Maitha, M. N. Gakinya, M. Cheang, J. O. Nydinya-Achola, P. Piot, R. C. Brunham, and F. A. Plummer. 1989. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. *Lancet* **ii**:403–407.
- Campagnari, A. A., L. M. Wild, G. E. Griffiths, R. J. Karalus, M. A. Wirth, and S. M. Spinola. 1991. Role of lipooligosaccharides in experimental dermal lesions caused by *Haemophilus ducreyi*. *Infect. Immun.* **59**:2601–2608.
- Chippendale, G. R., J. W. Warren, A. L. Trifillis, and H. L. T. Mobley. 1994. Internalization of *Proteus mirabilis* by human renal epithelial cells. *Infect. Immun.* **62**:3115–3121.
- Cope, L. D., S. Lumley, J. L. Latimer, J. Klesney-Tait, M. K. Stevens, L. S. Johnson, M. Purven, J. R. S. Munson, T. Lagergard, J. D. Radolf, and E. J. Hansen. 1997. A diffusible cytotoxin of *Haemophilus ducreyi*. *Proc. Natl. Acad. Sci. USA* **94**:4056–4061.
- Cossart, P. 1994. *Listeria monocytogenes*: strategies for entry and survival in cells and tissues, p. 285–304. In B. Tindall (ed.), *Bailliere's clinical infectious diseases*, vol. 1. Bailliere, Philadelphia, Pa.
- Dutro, S. M., G. E. Wood, and P. A. Totten. 1999. Prevalence of, antibody response to, and protective immunity induced by *Haemophilus ducreyi* hemolysin. *Infect. Immun.* **67**:3317–3328.
- Gibson, B. W., A. A. Campagnari, W. Melaugh, N. J. Phillips, M. A. Apicella, S. Grass, J. Wang, K. L. Palmer, and J. R. S. Munson. 1997. Characterization of a transposon Tn916-generated mutant of *Haemophilus ducreyi* 35000 defective in lipooligosaccharide biosynthesis. *J. Bacteriol.* **179**:5062–5071.
- Hansen, E. J., J. L. Latimer, S. E. Thomas, M. Helminen, W. L. Albritton, and J. D. Radolf. 1992. Use of electroporation to construct isogenic mutants of *Haemophilus ducreyi*. *J. Bacteriol.* **16**:5442–5449.
- High, N., J. Mounier, M. Prevost, and P. Sansonetti. 1992. IpaB of *Shigella flexneri* causes entry into epithelial cells and escape from the phagocytic vacuole. *EMBO J.* **11**:1991–1999.
- Hirono, I., N. Tange, and T. Aoki. 1997. Iron-regulated haemolysin gene from *Edwardsiella tarda*. *Mol. Microbiol.* **24**:851–856.
- Hoisteth, S. K., and B. A. D. Stocker. 1981. Aromatic-dependent *Salmonella typhimurium* are non-virulent and effective as live vaccines. *Nature* **291**:238–239.
- Konig, W., Y. Faltin, J. Scheffer, H. Schoffler, and V. Braun. 1987. Role of cell-bound hemolysin as a pathogenicity factor for *Serratia* infections. *Infect. Immun.* **55**:2554–2561.
- Korth, M. J., R. A. Schneider, and S. L. Mosely. 1991. An F41-K88-related genetic determinant of bovine septicemic *Escherichia coli* mediates expression of CS31A fimbriae and adherence to epithelial cells. *Infect. Immun.* **59**:2333–2340.
- Lammel, C. J., N. P. Dekker, J. Palefsky, and G. F. Brooks. 1993. *In vitro* model of *Haemophilus ducreyi* adherence to and entry into eukaryotic cells of genital origin. *J. Infect. Dis.* **167**:642–650.
- Morse, S. A. 1989. Chancroid and *Haemophilus ducreyi*. *Clin. Microbiol. Rev.* **2**:137–157.
- Palmer, K. L., W. E. Goldman, and J. R. S. Munson. 1996. An isogenic hemolysin-deficient mutant of *Haemophilus ducreyi* lacks the ability to produce cytopathic effects on human foreskin fibroblasts. *Mol. Microbiol.* **21**: 13–19.
- Palmer, K. L., S. Grass, and J. R. S. Munson. 1994. Identification of a hemolytic activity elaborated by *Haemophilus ducreyi*. *Infect. Immun.* **62**: 3041–3042.
- Palmer, K. L., and J. R. S. Munson. 1995. Cloning and characterization of the genes encoding the hemolysin of *Haemophilus ducreyi*. *Mol. Microbiol.* **18**:821–830.

24. Palmer, K. L., A. C. Thornton, K. R. Fortney, A. F. Hood, J. R. S. Munson, and S. M. Spinola. 1998. Evaluation of an isogenic hemolysin-deficient mutant in the human model of *Haemophilus ducreyi* infection. *J. Infect. Dis.* **178**:191–199.
25. Plummer, F. A., J. N. Simonsen, D. W. Cameron, J. O. Ndinya-Achola, J. K. Kreiss, M. N. Gakinya, P. Waiyaki, M. Cheang, P. Piot, A. R. Ronald, and E. N. Ngugi. 1991. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. *J. Infect. Dis.* **163**:233–239.
26. Poole, K., and V. Braun. 1988. Iron regulation of *Serratia marcescens* hemolysin gene expression. *Infect. Immun.* **56**:2967–2971.
27. Poole, K., E. Schiebel, and V. Braun. 1988. Molecular characterization of the hemolysin determinant of *Serratia marcescens*. *J. Bacteriol.* **170**:3177–3188.
28. Purcell, B. K., J. A. Richardson, J. D. Radolf, and E. J. Hansen. 1991. A temperature-dependent rabbit model for production of dermal lesions by *Haemophilus ducreyi*. *J. Infect. Dis.* **164**:359–367.
29. Purven, M., and T. Lagergard. 1992. *Haemophilus ducreyi*, a cytotoxin-producing bacterium. *Infect. Immun.* **60**:1156–1162.
30. Ruiz, N., B. Want, A. Pentland, and M. Caparon. 1998. Streptolysin O and adherence synergistically modulate proinflammatory responses of keratinocytes to group A streptococci. *Mol. Microbiol.* **27**:337–346.
31. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
32. Schiebel, E., H. Schwarz, and V. Braun. 1989. Subcellular location and unique secretion of the hemolysin of *Serratia marcescens*. *J. Biol. Chem.* **264**:16311–16320.
33. Schonherr, R., M. Hilger, S. Broer, R. Benz, and V. Braun. 1994. Interaction of *Serratia marcescens* hemolysin (ShlA) with artificial and erythrocyte membranes. *Eur. J. Biochem.* **223**:655–663.
34. Spinola, S. M., A. Orazi, J. N. Arno, K. Fortney, O. Kotylo, C. Chen, A. A. Campagnari, and A. F. Hood. 1996. *Haemophilus ducreyi* elicits a cutaneous infiltrate of CD4 cells during experimental human infection. *J. Infect. Dis.* **173**:394–402.
35. Spinola, S. M., L. M. Wild, M. A. Apicella, A. A. Gaspari, and A. A. Campagnari. 1994. Experimental human infection with *Haemophilus ducreyi*. *J. Infect. Dis.* **169**:1146–1150.
36. Strauss, E. J., N. Ghorri, and S. Falkow. 1997. An *Edwardsiella tarda* strain containing a mutation in a gene with homology to *shlB* and *hpmB* is defective for entry into epithelial cells in culture. *Infect. Immun.* **65**:3924–3932.
37. Strickberger, M. W. 1985. Genetics, 3rd ed. Macmillan Publishing Co., New York, N.Y.
38. Swihart, K. G., and R. A. Welch. 1991. Cytotoxic activity of the *Proteus* hemolysin HpmA. *Infect. Immun.* **58**:1861–1869.
39. Totten, P. A., J. C. Lara, D. V. Norn, and W. E. Stamm. 1994. *Haemophilus ducreyi* attaches to and invades cultured human foreskin epithelial cells in vitro. *Infect. Immun.* **62**:5632–5640.
40. Totten, P. A., W. R. Morton, G. H. Knitter, A. M. Clark, N. B. Kiviat, and W. E. Stamm. 1994. A primate model for chancroid. *J. Infect. Dis.* **169**:1284–1290.
41. Totten, P. A., D. V. Norn, and W. E. Stamm. 1995. Characterization of the hemolytic activity of *Haemophilus ducreyi*. *Infect. Immun.* **63**:4409–4416.
42. Totten, P. A., and W. E. Stamm. 1994. Clear broth and plate media for culture of *Haemophilus ducreyi*. *J. Clin. Microbiol.* **32**:2019–2023.
43. Trees, D. L., and S. A. Morse. 1995. Chancroid and *Haemophilus ducreyi*: an update. *Clin. Microbiol. Rev.* **8**:357–375.
44. Uphoff, T. S., and R. A. Welch. 1990. Nucleotide sequencing of the *Proteus mirabilis* calcium-independent hemolysin genes (*hpmA* and *hpmB*) reveals sequence similarity to the *Serratia marcescens* hemolysin genes (*shlA* and *shlB*). *J. Bacteriol.* **172**:1206–1216.
45. Wasserheit, J. N. 1992. Epidemiological synergy. Interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. *Sex. Transm. Dis.* **19**:61–77.
46. Welch, R. A. 1991. Pore-forming cytolysins of Gram-negative bacteria. *Mol. Microbiol.* **5**:521–528.
47. Welch, R. A., C. Forestier, A. Lobo, S. Pellett, J. W. Thomas, and G. Rowe. 1992. The synthesis and function of the *Escherichia coli* hemolysin and related RTX exotoxins. *FEMS Microbiol. Immunol.* **105**:29–36.
48. Willson, P. J., W. L. Albritton, L. Slaney, and J. K. Setlow. 1989. Characterization of a multiple antibiotic resistance plasmid from *Haemophilus ducreyi*. *Antimicrob. Agents Chemother.* **33**:1627–1630.

Editor: E. I. Tuomanen